Revive Therapeutics' experimental COVID treatment fails in late-stage study (updated)

Revive Therapeutics

06/07/2023 12:18

(Adds details on plans for treatment and background in
paragraphs 2-5)
       July 6 (Reuters) - Canada-based Revive Therapeutics
 RVV.CD  said on Thursday its experimental COVID-19 treatment
did not meet the main goal of a late-stage study.
    The company was evaluating the safety and efficacy of its
oral treatment, bucillamine, in the study which enrolled 713
patients with mild to moderate COVID-19.
    Earlier in May, Revive Therapeutics said it was halting the
study as it was likely that it would not meet the main goal
based on the recommendation of an independent data safety
monitoring board.
    The company said on Thursday it was pursuing certain
initiatives including partnerships and government support to
continue the development of bucillamine.
    Revive Therapeutics said it is reformulating bucillamine in
an intravenous and inhaled version targeting rare disorders
including a blood circulation disorder known as
ischemia-reperfusion injury and acute respiratory distress
syndrome.

 (Reporting by Sriparna Roy in Bengaluru; Editing by Shounak
Dasgupta)
 ((Sriparna.Roy@thomsonreuters.com))